Ticking Clock

 Targeted Immuno-Oncology



See Below For A Brief Introduction


Dorna Therapeutics is the first company to stimulate both innate and adaptive immune responses directly and selectively within solid tumors to create a universal therapeutic cancer vaccine.  The systemic administration of a single drug compound with tumor accumulating capabilities will allow patients to immunize themselves against their own cancers for a long lasting curative effect.


The in situ (“in place”) immunization mechanism has been scientifically understood for several years, but no company beside Dorna has the capability of targeted delivery of the therapeutic compounds directly to the tumor microenvironment to achieve this curative effect. 

More to come soon ...